Stephen L. Sabba - Jun 9, 2023 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: /s/ Stephen L. Sabba
Stock symbol
LGND
Transactions as of
Jun 9, 2023
Transactions value $
$0
Form type
4
Date filed
6/21/2023, 09:28 AM
Previous filing
May 12, 2023
Next filing
Mar 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +1.14K +4.43% $0.00 26.9K Jun 9, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Award $0 -5.46K -50% $0.00 5.46K Jun 9, 2023 Common Stock 5.46K $73.76 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities, as represented in Column 5, include a grant of 1,142 restricted share units approved by the Board of Directors of the Company at the 2023 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date.
F2 These securities, as represented in Column 5, were acquired by a grant of 5,461 shares approved by the Board of Directors of the Company at the 2023 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time.

Remarks:

The delay in filing was due to inadvertent oversight and this filing is being made at the earliest upon awareness of same.